IMVT vs. MDGL

Last updated Apr 1, 2026

Compare and contrast key facts about Immunovant, Inc. (IMVT) and Madrigal Pharmaceuticals, Inc. (MDGL).

Performance

IMVT vs. MDGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immunovant, Inc. (IMVT) and Madrigal Pharmaceuticals, Inc. (MDGL). The values are adjusted to include any dividend payments, if applicable.

IMVT vs. MDGL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
IMVT Immunovant, Inc.	-2.28%	2.62%	-41.21%	137.35%	108.33%	-81.55%	191.05%	-0.69%
MDGL Madrigal Pharmaceuticals, Inc.	-10.11%	88.72%	33.36%	-20.28%	242.52%	-23.77%	22.02%	2.61%

Fundamentals

Market Cap IMVT : $4.51B MDGL : $11.74B
EPS IMVT : -$2.65 MDGL : -$12.88
PB Ratio IMVT : 4.57 MDGL : 19.49
Total Revenue (TTM) IMVT : $0.00 MDGL : $958.40M
Gross Profit (TTM) IMVT : -$105.00K MDGL : $902.26M
EBITDA (TTM) IMVT : -$372.49M MDGL : -$300.10M

Returns By Period

In the year-to-date period, IMVT achieves a -2.28% return, which is significantly higher than MDGL's -10.11% return.

IMVT

• 1D: 5.48%
• 1M: -10.42%
• YTD: -2.28%
• 6M: 54.09%
• 1Y: 45.35%
• 3Y*: 17.00%
• 5Y*: 8.07%
• 10Y*: —

MDGL

• 1D: 3.59%
• 1M: 21.17%
• YTD: -10.11%
• 6M: 14.13%
• 1Y: 58.04%
• 3Y*: 29.28%
• 5Y*: 34.58%
• 10Y*: 50.55%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

IMVT vs. MDGL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMVT

IMVT Risk / Return Rank: 69
IMVT Sharpe Ratio Rank: 69
IMVT Sortino Ratio Rank: 69
IMVT Omega Ratio Rank: 63
IMVT Calmar Ratio Rank: 72
IMVT Martin Ratio Rank: 70

MDGL

MDGL Risk / Return Rank: 78
MDGL Sharpe Ratio Rank: 81
MDGL Sortino Ratio Rank: 80
MDGL Omega Ratio Rank: 75
MDGL Calmar Ratio Rank: 78
MDGL Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMVT vs. MDGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and Madrigal Pharmaceuticals, Inc. (MDGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMVT	MDGL	Difference
Sharpe ratio Return per unit of total volatility	0.82	1.28	-0.46
Sortino ratio Return per unit of downside risk	1.55	2.09	-0.54
Omega ratio Gain probability vs. loss probability	1.17	1.24	-0.07
Calmar ratio Return relative to maximum drawdown	1.59	2.03	-0.44
Martin ratio Return relative to average drawdown	3.36	4.45	-1.09
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IMVT vs. MDGL - Sharpe Ratio Comparison

The current IMVT Sharpe Ratio is 0.82, which is lower than the MDGL Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of IMVT and MDGL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	IMVT	MDGL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.82	1.28	-0.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.11	0.26	-0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.42	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.09	0.03	+0.07

Correlation

The correlation between IMVT and MDGL is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

IMVT vs. MDGL - Dividend Comparison

Neither IMVT nor MDGL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

IMVT vs. MDGL - Drawdown Comparison

The maximum IMVT drawdown since its inception was -93.59%, roughly equal to the maximum MDGL drawdown of -98.40%. Use the drawdown chart below to compare losses from any high point for IMVT and MDGL.

Drawdown Indicators

	IMVT	MDGL	Difference
Max Drawdown Largest peak-to-trough decline	-93.59%	-98.40%	+4.81%
Max Drawdown (1Y) Largest decline over 1 year	-20.98%	-29.36%	+8.38%
Max Drawdown (5Y) Largest decline over 5 years	-79.94%	-61.41%	-18.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-82.19%	—
Current Drawdown Current decline from peak	-52.87%	-13.16%	-39.71%
Average Drawdown Average peak-to-trough decline	-54.24%	-58.97%	+4.73%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.49%	13.41%	-2.92%

Volatility

IMVT vs. MDGL - Volatility Comparison

Immunovant, Inc. (IMVT) has a higher volatility of 14.73% compared to Madrigal Pharmaceuticals, Inc. (MDGL) at 13.96%. This indicates that IMVT's price experiences larger fluctuations and is considered to be riskier than MDGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IMVT	MDGL	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.73%	13.96%	+0.77%
Volatility (6M) Calculated over the trailing 6-month period	37.06%	32.63%	+4.43%
Volatility (1Y) Calculated over the trailing 1-year period	56.17%	45.66%	+10.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.18%	133.38%	-58.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.70%	119.65%	-41.95%

Financials